Manufacturer:
Sandoz
Route of Administration:
Subcutaneous
Site of Care:
Outpatient
Website:
Approved Indication:
- reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
- reducing signs and symptoms in adult patients with active ankylosing spondylitis
- treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
- treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
- treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older
- treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
- Uveitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology